ABOUT THIS EPISODE
Join Ropes & Gray’s life sciences and health care attorneys for a podcast series exploring regulatory, compliance, and enforcement changes emanating from Washington, D.C. and the potential impact on life sciences companies in 2024. In this second episode, we focus on key issues to watch related to product development, approval, and drug pricing in 2024. These include FDA activities aimed at expediting the development of drugs to treat rare diseases, changes to FDA’s accelerated approval program, clinical trial diversity initiatives, actions to support use of real-world evidence, and developments in drug pricing and market access as CMS works to implement the Medicare Price Negotiation Program and prepares for the Medicare Part D redesign.
English
United States
TRANSCRIPT 🔗
Kellie Combs: Hello, and welcome to Non-binding Guidance, our 2024 U.S. life sciences regulatory outlook podcast series. I’m Kellie Combs. I’m a partner in the life sciences regulatory and compliance practice group at Ropes & Gray based in D.C. I’m joined today by my colleague Sarah Blankstein, also in our life sciences regulatory and compliance group based in Boston, and Margaux Hall, a partner in our health care practice based with me in Washington.
Today, we’ll focus on anticipated developm…
Today, we’ll focus on anticipated developm…
SEARCH PAST EPISODES
Search past episodes of Non-binding Guidance.
Disclaimer: The podcast and artwork embedded on this page are from Ropes & Gray LLP, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
